RxDoctor Payments Data

Tina Valentine

Nurse Practitioner · Columbia, ILNPI 1356337224

Payments from drug & device makers

$1,847in general payments, 2019–2025

Across 99 payments — averaging $18.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$225
  • AstraZeneca$183
  • Lilly USA, LLC$154
  • Idorsia Pharmaceuticals US Inc$137
  • Boston Scientific$104
  • GSK$102
  • plus $940 from 25 others

What the payments were for

  • Food & beverage$1,847100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,847 in reported general payments places this provider in the 85th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$28,074
Medicare patients
149
Services billed
299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin34$37,265
EliquisApixaban24$22,871
OzempicSemaglutide16$14,276
TradjentaLinagliptin16$11,947
FarxigaDapagliflozin Propanediol11$10,932
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,208
SymbicortBudesonide/Formoterol Fumarate11$2,722
Atorvastatin Calcium228$2,433
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$2,295
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$1,929
Albuterol Sulfate HfaAlbuterol Sulfate66$1,659
Losartan Potassium179$1,379
Levothyroxine Sodium118$1,272
Celecoxib13$1,087
Gabapentin69$962

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$22,87124 claims
Novo NordiskOzempic$225$14,27616 claims
AstraZenecaFarxiga, Symbicort$183$13,65422 claims
GSKTrelegy Ellipta$102$10,20816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Columbia

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →